Glioma is the most common primary malignant tumor in the central nervous system. In 2023, GBM included it in the second batch of the National Rare Disease List, seriously affecting human life safety and quality of life. In recent years, with the decentralization of glioma diagnosis and treatment norms, research and innovation in drug combination, the advancement of new technologies and brain science, as well as the establishment and support of MDT multidisciplinary medical centers, the treatment methods and models for glioma have also ushered in new opportunities. This conference, themed "Medical Heritage Passed Down, United as One", sets up two main axes: two norms and innovation. It invites renowned experts and scholars in the field of glioma from home and abroad to deliver keynote speeches and profound remarks on various aspects such as quality standards, rare disease management, drug combination, cell therapy, radiotherapy, and the construction of MDT centers. The Chengdu High-tech Medical Association successfully held an academic conference online on November 5, 2025, titled "Medical Heritage Passed Down, United as One - Diagnosis and Treatment Standards and Clinical Application Practice of Glioma". It aims to build a platform for experts and colleagues to exchange and learn from each other, draw on the strengths of others, and seek common development.